Thurston, Springer, Miller, Herd & Titak, Inc. Beam Therapeutics Inc. Transaction History
Thurston, Springer, Miller, Herd & Titak, Inc.
- $330 Million
- Q3 2024
A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 97 shares of BEAM stock, worth $2,813. This represents 0.0% of its overall portfolio holdings.
Number of Shares
97
Previous 97
-0.0%
Holding current value
$2,813
Previous $2,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding BEAM
# of Institutions
236Shares Held
75.2MCall Options Held
438KPut Options Held
232K-
Farallon Capital Management LLC San Francisco, CA8.21MShares$238 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.84MShares$228 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$221 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.53MShares$189 Million1.52% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.83MShares$140 Million71.21% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $2.04B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...